🇺🇸 Loqtorzi in United States

FDA authorised Loqtorzi on 30 October 2024

Marketing authorisations

FDA — authorised 30 October 2024

Application: BLA761240
Marketing authorisation holder: COHERUS BIOSCIENCES INC
Indication: Labeling
Status: approved

The FDA approved Loqtorzi, a product of Coherus Biosciences Inc, on 2024-10-30. The approval was granted through a standard expedited pathway. However, the specific indication approved for Loqtorzi is not reported in the available data.

Read official source →

FDA

Marketing authorisation holder: COHERUS BIOSCIENCES INC
Status: approved

Loqtorzi in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Loqtorzi approved in United States?

Yes. FDA authorised it on 30 October 2024; FDA has authorised it.

Who is the marketing authorisation holder for Loqtorzi in United States?

COHERUS BIOSCIENCES INC holds the US marketing authorisation.